Group 1: Financial Performance - In Q1 2025, the company's revenue decreased by 15.31% compared to the same period in 2024, primarily due to a decline in demand for antibiotics and the impact of the "Four Same" policy on product sales and pricing [1] - The total revenue for 2024 saw a year-on-year decline of 5.41%, attributed to the exit of the product Zuo Yi from the hospital market due to centralized procurement [1] Group 2: Product Development and R&D - The company has received approval for clinical trials of the injectable ALK-N001 from the National Medical Products Administration [3] - R&D investment in 2024 is expected to increase significantly due to new investments in innovative drugs and improvements in existing drugs [9] - The compound α-keto acid tablets were selected in the tenth batch of national procurement, with a selected price of 8.52 CNY per box and an estimated procurement volume of 800 million boxes [8] Group 3: Export and Market Strategy - In 2024, the company's export sales amounted to 398 million CNY, accounting for 25.85% of total revenue, with a significant portion of the subsidiary Keri Bio's revenue coming from overseas clients [10] - The company plans to leverage its brand influence to expand the market for Zuo Yi outside hospitals [2] Group 4: Future Expectations - The company aims to enhance sales in 2025 through selected products from national procurement and new products with technical barriers, such as Sacubitril/Valsartan tablets [11] - The animal health technology sector is currently in a loss phase but is expected to become a new growth point as new products are approved and launched [12]

Group 1: Financial Performance - The company's net profit, when combined with R&D expenses, has remained stable or slightly increased over recent years despite challenges in the pharmaceutical industry [1][2] - The raw material drug business has remained stable, while the specialty intermediate business has shown significant performance [2] - The sales volume and price of Benzylsulfonyl L-lysine tablets have been significantly impacted since the second half of 2023 due to national procurement policies [2] Group 2: R&D and Product Development - The company plans to shift focus from generic drugs to improved new drugs and innovative drugs, aiming for a "generic-innovative synergy" strategy [2] - The R&D budget for 2025 is expected to remain high, with Q1 R&D expenses reported at 51.8 million yuan [7] - The company has received approval for clinical trials of ALK-N001, indicating progress in its innovative drug pipeline [3][7] Group 3: Market Strategy and Product Launches - The company aims to leverage its existing brand influence to expand the market for L-lysine tablets, focusing on outpatient sales channels [4] - New products with technical barriers, such as Sacubitril/Valsartan tablets, have been launched, with future sales dependent on various market factors [3] - The company is actively pursuing new drug registrations in the pet medicine sector, with plans to double sales in 2024 [3] Group 4: Regulatory and Policy Impact - The company is preparing for the 11th batch of national procurement policies, which have not yet been announced [8] - The impact of the "Four Consistencies" policy has led to a decline in sales and prices for certain products, but the company expects stabilization as policies mature [4][8] - The export revenue accounted for 25.85% of total revenue in 2024, with significant markets including the U.S. and Europe [5]

证券代码：002940 证券简称：昂利康 公告编号：2025-034 浙江昂利康制药股份有限公司 关于第一期员工持股计划存续期即将届满的提示性公告 2022 年 11 月 15 日、2023 年 5 月 19 日，公司分别实施了 2022 年半年度权 益分派、2022 年年度权益分派，以权益分派时公司总股本为基础以资本公积金 向全体股东每 10 股转增 4.5 股，两次权益分派分别转增 43,176,068 股和 1 62,605,299 股。权益分派实施完成后，公司第一期员工持股计划所持股份数变更 为 4,331,150 股，占公司目前总股本的 2.15%。具体内容详见公司在指定信息披 露媒体《证券时报》及巨潮资讯网（www.cninfo.com.cn）上刊载的相关公告。 根据《浙江昂利康制药股份有限公司第一期员工持股计划（草案）》的相关 规定，本员工持股计划所获标的股票的锁定期为 12 个月（即 2022 年 11 月 3 日 至 2023 年 11 月 2 日），自公司公告最后一笔标的股票过户至员工持股计划名下 之日起计算。公司本员工持股计划锁定期已于 2023 年 11 月 2 日届满，具体内容 详见 ...

生产企业名称：浙江昂利康制药股份有限公司 证券代码：002940 证券简称：昂利康 公告编号：2025-033 浙江昂利康制药股份有限公司 关于获得化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 近日，浙江昂利康制药股份有限公司（以下简称"公司"）收到国家药品监 督管理局（以下简称"国家药监局"）签发的《化学原料药上市申请批准通知书》。 现就相关情况公告如下： 一、批件基本信息 化学原料药名称：多潘立酮 登记号：Y20230000585 公司本次获得化学原料药多潘立酮上市申请批准通知书，将进一步丰富公司 产品线，提升公司核心竞争力。本次获得该药物上市申请批准通知书，对本公司 当期业绩无重大影响。 由于药品研发、生产和销售容易受到国家政策、市场环境等因素影响，具有 较大不确定性，敬请广大投资者谨慎决策，注意防范投资风险。 生产企业地址：绍兴嵊州市嵊州大道北 1000 号 申请内容：境内生产化学原料药上市申请 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。 二、产品基本情况 ...

昂利康（002940）公告，2025年第一季度营收为3.46亿元，同比下降15.31%；净利润为1590.61万元， 同比下降43.63%。 ...

Financial Performance - The company's revenue for Q1 2025 was ¥345,526,779.17, a decrease of 15.31% compared to ¥407,993,014.11 in the same period last year[4] - Net profit attributable to shareholders was ¥15,906,128.54, down 43.63% from ¥28,218,693.81 year-on-year[4] - Basic and diluted earnings per share decreased by 42.86% to ¥0.08 from ¥0.14 in the same period last year[4] - Net profit for the current period is ¥25,743,581.00, compared to ¥47,410,347.34 in the previous period, indicating a decline of approximately 45.5%[21] - Total operating revenue for the current period is ¥345,526,779.17, down from ¥407,993,014.11 in the previous period, representing a decrease of approximately 15.3%[20] - Total operating costs decreased to ¥328,054,513.62 from ¥364,384,558.95, a reduction of about 10%[20] Cash Flow - The net cash flow from operating activities was ¥29,901,970.48, representing a significant decline of 81.46% from ¥161,258,174.92 in the previous year[4] - Operating cash flow for the current period is ¥29,901,970.48, a decrease of 81.5% compared to ¥161,258,174.92 in the previous period[22] - Total cash inflow from operating activities is ¥402,132,818.90, down 12.8% from ¥461,825,250.09 year-over-year[22] - Cash outflow from operating activities increased to ¥372,230,848.42, compared to ¥300,567,075.17 in the previous period, representing a 23.9% increase[22] - Net cash flow from financing activities increased by 58.75% to ¥19,006,130.22, mainly due to new loans obtained during the period[13] - Cash inflow from financing activities totaled ¥140,450,000.00, up from ¥118,414,427.89 in the previous period, marking an increase of 18.6%[23] - The ending balance of cash and cash equivalents is ¥344,396,726.59, down from ¥971,924,461.13 in the previous period, a decrease of 64.6%[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,918,389,809.54, a decrease of 1.89% from ¥2,974,532,155.08 at the end of the previous year[4] - Total liabilities decreased to ¥1,112,302,793.08 from ¥1,176,112,275.01, a decline of approximately 5.5%[19] - Total equity increased to ¥1,806,087,016.46 from ¥1,798,419,880.07, reflecting a growth of about 0.4%[19] - Cash and cash equivalents in current assets decreased to ¥1,445,696,715.01 from ¥1,498,867,441.24, a decline of approximately 3.5%[19] - Long-term equity investments slightly decreased to ¥246,451,828.79 from ¥249,050,486.56, a reduction of about 1.0%[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 12,266[14] - The largest shareholder, Shenzhou Juntai Investment Co., Ltd., holds 35.44% of shares, totaling 71,485,000 shares[14] - The company repurchased 4,840,000 shares, representing 2.40% of the total share capital[15] Investments and Other Activities - The company reported a 142.89% increase in trading financial assets, totaling ¥87,540,986.58 due to increased investment in financial products[10] - Accounts receivable decreased by 32.06% to ¥128,082,542.63, primarily due to improved collection of receivables[10] - The company has reduced its stake in Zhejiang Haichang Biological Technology Co., Ltd. from 5.6201% to 5.2443% after waiving its preemptive rights in a capital increase[16] - The company plans to increase the registered capital of Zhejiang Anglikang Animal Health Technology Co., Ltd. by ¥10 million, raising its total capital from ¥40 million to ¥50 million[15] Inventory and Prepayments - The company's inventory stands at ¥464,381,523.49, a decrease from ¥503,792,116.03 at the beginning of the period[17] - The company's accounts receivable decreased to ¥128,082,542.63 from ¥188,526,737.92[17] - The company’s trading financial assets increased to ¥87,540,986.58 from ¥36,040,986.58[17] - The company’s prepayments decreased to ¥11,842,507.61 from ¥16,177,618.16[17] Research and Development - Research and development expenses increased to ¥51,800,372.24 from ¥49,086,015.25, reflecting a growth of about 3.5%[21] Audit Information - The company did not undergo an audit for the first quarter report[24]

Core Viewpoint - Zhejiang Anglikang Pharmaceutical Co., Ltd. reported a revenue of 1.538 billion yuan and a net profit of 80.3345 million yuan for 2024, reflecting a year-on-year decline of 41.94% in net profit primarily due to increased R&D expenditures [1] Group 1: Financial Performance - The company achieved a revenue of 1.538 billion yuan in 2024 [1] - The net profit attributable to shareholders was 80.3345 million yuan, down 41.94% year-on-year [1] - R&D expenses reached 231 million yuan, an increase of 33.74% year-on-year, accounting for 14.99% of total revenue [1] Group 2: R&D and Innovation - Anglikang secured 19 new invention patents in 2024 and participated in drafting national standards for pharmaceutical excipients [2] - The company received drug registration certificates for six products, including phosphate sitagliptin tablets and sacubitril valsartan sodium tablets [2] - Anglikang is accelerating its transformation towards innovative drugs, collaborating with Shanghai Qinhuli Biotechnology Co., Ltd. on the development of ALK-N001/QHL-1618 [2] Group 3: Industry Upgrades and Pet Medicine - The company is advancing technology upgrades with a focus on "raw materials + formulations" integration, optimizing processes to reduce energy consumption [3] - Significant progress was made in the pet medicine sector, with several products receiving GMP certification and approval numbers [3] - Anglikang is developing innovative vaccines for pets in collaboration with China Agricultural University, and a chronic pain rehabilitation software project has entered the registration application phase [3]

证券代码：002940 证券简称：昂利康 公告编号：2025-031 浙江昂利康制药股份有限公司 关于创新药注射用 ALK-N001 获得药物临床试验 批准通知书的公告 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 | | --- | | 误导性陈述或重大遗漏。 | 近日，浙江昂利康制药股份有限公司（以下简称"公司"）收到国家药品监 督管理局（以下简称"国家药监局"）签发的注射用 ALK-N0011《药物临床试 验批准通知书》，现将有关情况公告如下： 一、基本情况 | 药品名称 | | 申请事项 | 规格 | 受理号 | | --- | --- | --- | --- | --- | | 注射用 | ALK-N001 | 境内生产药品注册临床试验 | 10mg | CXHL2500201 | 根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 2 月 17 日受理的注射用 ALK-N001 临床试验申请符合药品注册的有关要求，同意本品 开展晚期实体瘤的临床试验。 告编号：2024-008）、《关于创新药注射用 ALK-N001 临床试验申请获得受理的 公告》（公告 ...

改良型新药方面，ALKA016-1、NHKC-1的Ⅲ期临床试验顺利推进中，BM2216完成了Ⅰ期临床试验。 创新药方面，公司与亲合力就ALK-N001/QHL-1618的授权达成一致，公司获得了该产品在中国(含港、 澳、台地区)的全部权益，并推动该产品顺利完成了临床前研究。 报告期内，公司及子公司共有25个产品完成药品再注册，新获得发明专利19项，公司子公司科瑞生物参 与起草了《胆固醇国家药用辅料标准》，其"制备胆固醇、其衍生物及类似物的方法"的PCT专利已在日 本和欧盟获得授权。 中证报中证网讯(王珞)4月25日晚间，昂利康（002940）发布2024年年报。2024年公司实现营业收入 15.38亿元，实现净利润8033.45亿元，实现扣非净利润4840.59万元。报告期内，公司持续加大研发投 入，总计研发投入为2.31亿元，同比增长33.74%，占当期营业收入比例为14.99%。 公告表示，公司自成立以来坚持研发和创新，坚定不移推动研发投入，历经多年发展，在化学制药领域 已积累了一批核心技术，并通过自主研发成功掌握了口服头孢类原料药的酶法生产工艺、缓控释制剂生 产工艺。数据显示，近年来公司研发投入持续保持 ...

Core Insights - The company achieved a revenue of 1.538 billion yuan and a net profit of 80.3345 million yuan in the 2024 annual report, with a proposed cash dividend of 0.125 yuan per share totaling 24.5136 million yuan [1] - The company emphasizes research and development (R&D) as a core growth driver, with R&D investment reaching 230.5208 million yuan, a 33.74% increase year-on-year, accounting for 14.99% of revenue, marking a record high since its listing [1] - The company is transitioning from a focus on generic drugs to a strategy combining specialty generics, modified new drugs, and innovative drugs, termed "co-innovation" [1][3] Business Strategy - The company adheres to a "dual-drive" strategy of raw materials and formulations, with main business areas including chemical raw materials, chemical formulations, pharmaceutical excipients, and specialty intermediates [2] - The company has significant advantages in oral cephalosporin raw materials, alpha-keto acid raw materials, cardiovascular formulations, inhalation anesthetics, and anti-androgen intermediates [2] Innovation and Development - The company is actively supported by government initiatives for innovative drugs, having reached an agreement with Qinhui on the authorization of ALK-N001/QHL1618, obtaining all rights in China [3] - The company plans to submit registration applications for modified new drugs ALKA016-1 and NHKC-1 in 2025 and initiate clinical trials for innovative drugs, enhancing its product line and profitability [3] Future Outlook - The company aims to become a modern pharmaceutical enterprise with high brand recognition, focusing on R&D transformation and improving operational efficiency through digitalization and intelligent technologies [4] - The company will continue to adapt to changing market conditions, actively participate in procurement and bidding, and enhance market promotion and product sales [4]